
Increased bone turnover and rapid bone loss follow discontinuation of denosumab. We investigated the long‐term efficacy of zoledronate (ZOL) in maintaining bone mineral density (BMD) after discontinuation of denosumab. In this randomized, open‐label, interventional study, we included 61 postmenopausal women and men older than 50 years discontinuing denosumab after 4.6 ± 1.6 years.
Like
Save
Share